Ishares Msci Brazil ETF vs Zoetis Inc — how do they compare? Ishares Msci Brazil ETF trades at $43.54 (market cap $11.30B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Zoetis Inc is far larger — about 2.7× Ishares Msci Brazil ETF's market cap, and Zoetis Inc pays a 2.9% dividend while Ishares Msci Brazil ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Zoetis Inc for 70 Days on average.
| EWZ | ZTS | |
|---|---|---|
Market Cap | $11.30B | $30.20B |
Volume | 44,036,597 | 6,175,327 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.54 | $147.53 |
52-Week Low | $28.79 | $69.09 |
Typical Hold Time | 50 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $42.59, up 0.52% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF is heavily influenced by Brazil's upcoming October 2026 election, with institutional investors accumulating call options betting on a favorable outcome. Recent news highlights EWZ as a diversifier from U.S. tech exposure, though it faces competition from lower-fee alternatives like FLBR.
The outlook for EWZ hinges on Brazil's election result and commodity trends, offering asymmetric upside if pro-market policies prevail. Key risks include political volatility, U.S. tariff impacts, and currency fluctuations. Wall Street sentiment is cautiously optimistic, with unusual options activity signaling speculative interest in near-term gains.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →